Skip to main content
Caplight Logo









Xevant

Xevant

Private
Lehi, UtahHealthcare & Life Scienceshttps://www.xevant.com/

Last Round

Series A

Feb 8, 2024

Total Funding Raised

$17.22M

Company Overview

Xevant is a healthcare technology company that provides a real-time, AI-powered analytics platform for organizations managing pharmacy benefits.

Sector

Healthcare & Life Sciences

Verticals

Healthcare Analytics, Vertical SaaS, Business Intelligence, Workflow Automation

Business Model

B2B

Customer Profile

Subscription SaaS, Usage-Based SaaS

AI Layer

Application

Keywords

pharmacy benefit managementPBMpharmacy spend managementhealthcare analyticspharmacy benefit optimizationreal-time monitoringpharmacy cost containmentthird-party administratorTPApharmacy claim analyticsvertical SaaShealthcare cost transparencybenefit plan auditpharmacy auditPBM audit

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Xevant Comparables

Compare Xevant with similar companies based on industry and business-model similarity.

Xevant comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Scripta Insights
79%
Truveris
76%
McKesson
71%

Xevant Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AFeb 8, 2024
Growth EquityMar 14, 2023
Series ADec 29, 2021
VC RoundJan 6, 2021

Key People

Founding team and executive leadership

Scott Sorensen

Chief Technology Officer

Executive Team

Xevant Investors

Notable investors and investment history

Xevant investors
InvestorRounds
Decathlon Capital PartnersSeries A
Tech Council VenturesSeries A, VC Round
Boston Millennia PartnersVC Round
Martinson VenturesSeries A, VC Round
Boston Millennia PartnersSeries A, VC Round
HCAP PartnersSeries A, Growth Equity

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 29, 2026

    Named a 2025 Modern Healthcare Best in Business company.

  • Jun 11, 2025

    Launched VerX, a new platform for pharmacy benefit optimization.

Xevant Filings

Explore SEC and related filing metadata, where available.

Xevant filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Xevant's valuation, stock price, and market status.

Is Xevant a public or private company?

Xevant is a private company.

What is the current stock price of Xevant?

Xevant is a private company with no public stock price. No recent secondary market data is available.

How much is Xevant worth (valuation)?

Valuation information for Xevant is not publicly available.

Can I buy Xevant stock?

Xevant shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Xevant's last funding round?

Xevant's most recent funding round was Series A Extension on February 8, 2024.

Who are the main investors in Xevant?

Key investors in Xevant include Decathlon Capital Partners, Tech Council Ventures, Boston Millennia Partners, Martinson Ventures, HCAP Partners.

Will Xevant IPO soon?

No public IPO plans have been announced for Xevant.

How can I track Xevant secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Xevant's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLehi, Utah
Employee Range30
Year Founded2017
Last FundingFeb 8, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?